Law Office of Brodsky & Smith, LLC Announces Investigation of BioForm Medical, Inc

Document Sample
Law Office of Brodsky & Smith, LLC Announces Investigation of BioForm Medical, Inc Powered By Docstoc
					Law Office of Brodsky & Smith, LLC Announces Investi
BioForm Medical, Inc.
January 07, 2010 06:33 PM Eastern Time  

BEVERLY HILLS, Calif.--(EON: Enhanced Online News)--Law office of Brodsky & Smith, LLC announces that it is investigatin
against the Board of Directors of BioForm Medical Inc. (“BioForm” or the “Company”) (Nasdaq:BFRM) related to the merger agr
Pharma Group.

Under the terms of the transaction, BioForm stockholders will receive $5.45 in cash pursuant to a cash tender offer followed by a s
merger. The transaction is valued at approximately $253 million. The investigation concerns whether the board breached their fiduci
agreeing to various deal protections that may prevent other superior offers. These protections include restrictions on solicitation of al
proposals, a top-up option to acquire additional shares, the board’s agreement to pay a $8 million termination fee

If you are a BioForm shareholder and wish to discuss the legal ramifications of the Board’s actions, you may e-mail or call the law o
& Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, E
Smith, Esquire at Brodsky & Smith, LLC, 9595 Wilshire Blvd., Suite 900, Beverly Hills, CA 90212, by e-mail at clients@brodsky
calling toll free 877-LEGAL-90.

Contacts
Brodsky & Smith, LLC
Jason L. Brodsky, Esquire
Evan J. Smith, Esquire
877-LEGAL-90
clients@brodsky-smith.com

Permalink: http://eon.businesswire.com/news/eon/20100107007130/en

				
DOCUMENT INFO
Shared By:
Tags:
Stats:
views:19
posted:1/7/2010
language:English
pages:1
Description: BEVERLY HILLS, Calif.--(EON: Enhanced Online News)--Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of BioForm Medical Inc. (“BioForm” or the “Company”) (Nasdaq:BFRM) related to the merger agreement with Merz Pharma Group. Under the terms of the transaction, BioForm stockholders will receive $5.45 in cash pursuant to a cash tender offer followed by a second-step merger. The transaction is valued at approximately $253 milli a style='font-size: 10px; color:
EON: Enhanced Online News EON: Enhanced Online News http://eon.businesswire.com
About At EON: Enhanced Online News, we show you how to make your online press release thrive. If you want to drive traffic to your website, generate sales leads, make an announcement, or promote a new product, EON: Enhanced Online News delivers the online visibility that you need. EON: Enhanced Online News powered by Business Wire.